Pharma IQ Members

Market Access

Find out everything you need to know about the latest pricing, reimbursement and market access strategies that will drive your business development.

226 results
of 21
Contributor: Joyce El Hokayem
Posted: 21/11/2017
default profile icon
Human Genetics Scientist, Joyce El Hokayem examines the benefits phytomedicine could offer to today’s healthcare systems and the challenges researchers in this market face Full Content »
Contributor: Pharma IQ News
Posted: 31/10/2017
Pharma IQ News
Pharma IQ looks at the potential of artificial intelligence in drug discovery. Full Content »
Contributor: Katie Sadler
Posted: 31/10/2017
Katie Sadler
Indian pharmaceutical production expected grow 15 per cent by 2020 with domestic buying power sustaining revenues Full Content »
Contributor: Regina Au
Posted: 30/10/2017
Regina Au
While social media is taking the consumer world by storm, the medical industry has been a bit shy to fully embrace these channels because of regulatory requirements. Full Content »
Contributor: Dr Steven Bradshaw
Posted: 26/09/2017
Dr Steven Bradshaw
Pharma treads a fine line to the tipping point where there is insufficient time to recoup a drug’s costs, due to the number of years left that the patent can run. Full Content »
Contributor: Chanice Henry
Posted: 19/09/2017
Chan
As the globe’s health systems groan under financial pressure, analysts have identified large differences in the amounts European patients pay for generics. Full Content »
Contributor: Katie Sadler
Posted: 11/09/2017
Katie Sadler
Study reveals UK pharmacy scheme will provide long-term savings for National Health Service (NHS) England Full Content »
Contributor: Pharma IQ News
Posted: 06/09/2017
Pharma IQ News
As many pharma manufacturers are rushing to discover the next blockbuster treatment in personalized medicine, the US FDA has approved Kymriah – the first chimeric antigen receptor T cell (CAR-T) therapy. Full Content »
Contributor: Pharma IQ
Posted: 05/09/2017
Pharma IQ
As pharma spend continues to climb, so does public scrutiny on drug pricing. Once again, medicine manufacturers are spurred to strike a fair solution to balance raging its R&D appetites with affordable access to treatments for patients Full Content »
Contributor: Dane Hartung
Posted: 29/08/2017
Dane TN
Dane Hartung, Director Marketing and Access, Fougera Pharmaceuticals shares best practices for determining if and when you should implement a new Commercial Patient Access Program. Dane also discusses how you should go about ensuring your patient access program is ethical, compliant and effectively differentiates your product. Full Content »
Contributor: Ash Rishi
Posted: 14/08/2017
Ash Rishi
Customers enjoy interacting with brands on social media when it gives them great results: special offers, the chance to win prize draws, or a swift and generous response to a complaint. But, how can this experience - an increasingly important feature of consumer retail - be translated to the more tightly-regulated field of pharmaceuticals? Full Content »
226 results
of 21